Influenza Breastfeeding Study
The effect of flu immunization on the level of immunity against the flu in breastmilk, and how this may help protect a breastfeeding infant.
The effect of flu immunization on the level of immunity against the flu in breastmilk, and how this may help protect a breastfeeding infant.
Our goal is early identification of deviation from healthy brain development to allow targeted early intervention and improve developmental outcomes.
To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
To find out which of two commonly used IV fluids given in the Emergency Department for sepsis is most effective.
Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.
Two main purposes of the study: To see if serious bacterial infections occur less than once a year in each study subject. This will determine if study drug is effective. Also to find out if study drug is safe and tolerable for study subjects.
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.